Tissue microarrays for predictive molecular pathology
Open Access
- 1 August 2002
- journal article
- editorial
- Published by BMJ in Journal of Clinical Pathology
- Vol. 55 (8), 575-576
- https://doi.org/10.1136/jcp.55.8.575
Abstract
Preparing for a TITANIC problem The advent of a novel category of anticancer drugs targeting individual genes is greatly affecting pathology and it appears that a new discipline—predictive molecular pathology—will become important in our field. For example, Herceptin (trastuzamab) treatment can only be used against tumours expressing the HER-2 oncogene1 and STI571 (Glivec) is highly efficient against tumours expressing c-kit (CD117).2 Because these target genes can be expressed in many different tumour types, oncologists are now increasingly demanding HER-2 and c-kit analyses for all of their patients so that they can potentially benefit from new drugs. The number of such analyses, often performed many years after the removal of the primary tumour, increases rapidly as more patients with cancer and clinicians become aware of the potential availability of new “miracle” drugs. Currently, the demand for retrospective c-kit and HER-2 analyses can be met using the tools of traditional molecular pathology. However, what would happen if all living patients with cancer became aware of a new drug from which they could benefit if their tumour expressed one particular gene? The logistical problems connected to such a mass demand for analyses would be comparable to the situation on the sinking Titanic with a shortage of lifeboats more than 90 years ago. Alone in a small country like Switzerland (7000 000 inhabitants), there is an estimated number of > 150 000 living people with known potentially life threatening cancer. Tens of thousand of these patients would die of …Keywords
This publication has 9 references indexed in Scilit:
- Tissue microarrays: a new approach for quality control in immunohistochemistryJournal of Clinical Pathology, 2002
- Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinomaJournal of Clinical Pathology, 2002
- Tissue Microarrays for Rapid Linking of Molecular Changes to Clinical EndpointsThe American Journal of Pathology, 2001
- Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast CancerJNCI Journal of the National Cancer Institute, 2001
- High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer.2001
- Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughputin situ studiesThe Journal of Pathology, 2001
- Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal TumorNew England Journal of Medicine, 2001
- Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.Journal of Clinical Oncology, 1998
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998